Doctors and nurses celebrate end of chemo for 5-year-old with song
Slater Bushman, 5, is going home healthy after fighting high-risk neuroblastoma for more than 400 days. Doctors and nurses at St. Jude Children's Research Hospital in Memphis celebrated the fact that he's cancer free with a song. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 21, 2019 Category: Consumer Health News Source Type: news

New Experimental Therapy CAR NKT-Cells Tested In Cancer Patients For The First Time
Genetically modified Natural Killer cells have been used in humans for the first time to treat children with relapsed neuroblastoma. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 1, 2019 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Source Type: news

LSU Health New Orleans research finds new Rx target for childhood cancer
(Louisiana State University Health Sciences Center) Research led by Michael Lan, Ph.D., Professor of Pediatrics and Genetics at LSU Health New Orleans School of Medicine, found that a compound named 5'-iodotubercidin (5'-IT) suppresses the growth of neuroblastoma cells and identified a potential new therapeutic approach for the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2019 Category: Cancer & Oncology Source Type: news

Proton therapy shows efficacy, low toxicity in large cohort of children with high-risk neuroblastoma
(Children's Hospital of Philadelphia) Researchers from Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania analyzed the largest cohort to date of pediatric patients with high-risk neuroblastoma treated with proton radiation therapy (PRT), finding both that proton therapy was effective at reducing tumors and demonstrated minimal toxicity to surrounding organs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2019 Category: International Medicine & Public Health Source Type: news

Toddler is in remission from stage four cancer at just 21 months old
Molly Hughes was diagnosed with neuroblastoma just before she was five months old. Fifteen months and five rounds of surgery later, the Kentucky toddler is cancer-free at last. (Source: the Mail online | Health)
Source: the Mail online | Health - April 6, 2019 Category: Consumer Health News Source Type: news

Kentucky toddler's cancer in remission after long treatment
A 21-month-old Kentucky girl who was diagnosed with Stage 4 neuroblastoma more than a year ago has given her family reason to celebrate _ she is cancer-free (Source: ABC News: Health)
Source: ABC News: Health - April 5, 2019 Category: Consumer Health News Tags: Health Source Type: news

Irish girl, 14, who has been battling cancer for 12 years flies to the US for treatment
Robyn Smyth, 14, from Dublin, Ireland, was diagnosed with neuroblastoma at age three. She's relapsed four times since and the family is now flying to Michigan for treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - March 21, 2019 Category: Consumer Health News Source Type: news

Protein BRCA1 as a stress coach
(University of W ü rzburg) Two proteins work hand in hand to ensure that the tumor cells of neuroblastoma can grow at full speed. In Nature, a W ü rzburg research team shows how the proteins can do this. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 20, 2019 Category: Cancer & Oncology Source Type: news

Antibody-drug conjugate shows efficacy against cell surface protein in neuroblastoma
(Children's Hospital of Philadelphia) Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 13, 2019 Category: Biology Source Type: news

Washington girl, 5, cured of cancer after her dentist found her tumor during a routine cleaning
Hunter Jones, five, from Everett, Washington, was diagnosed with neuroblastoma, a cancer that forms in nerve tissue. After 18 months of treatment, she was declared cancer-free. (Source: the Mail online | Health)
Source: the Mail online | Health - March 7, 2019 Category: Consumer Health News Source Type: news

Scientists discover potential way to treat and prevent cancer in children (neuroblastoma)
(Children's Cancer Institute Australia) The MYCN oncogene is known to be a key cause of a number of deadly solid tumour cancers, including neuroblastoma which claims more lives of children under 5 than any other cancer. In new research, a team led by Professor Michelle Haber AM, Executive Director, and Professor Murray Norris AM, Deputy Director, Children's Cancer Institute, Australia, has uncovered a previously unknown crucial link between polyamines and MYCN, offering a new way to target childhood cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 1, 2019 Category: International Medicine & Public Health Source Type: news

England rugby stars lead heart-warming campaign for boy, 10, with cancer
Harry Banks, from Bedfordshire, was diagnosed in 2012 with neuroblastoma, a rare cancer which develops from specialised cells left behind from a baby's development in the womb. (Source: the Mail online | Health)
Source: the Mail online | Health - January 23, 2019 Category: Consumer Health News Source Type: news

Devon girl's nightly stomach aches turn out to be rare cancer
Cayla Jones, from Cullompton in Devon, was diagnosed with neuroblastoma last summer and has needed intensive chemotherapy, surgery and radiotherapy to try and tackle it. (Source: the Mail online | Health)
Source: the Mail online | Health - January 14, 2019 Category: Consumer Health News Source Type: news

Four-year-old girl's nightly stomach aches turn out to be rare cancer
Cayla Jones, from Cullompton in Devon, was diagnosed with neuroblastoma last summer and has needed intensive chemotherapy, surgery and radiotherapy to try and tackle it. (Source: the Mail online | Health)
Source: the Mail online | Health - January 14, 2019 Category: Consumer Health News Source Type: news

Donors of Rare Blood Type Sought to Save a Miami Toddler
Zainab Mughal, 2, has cancer. Her treatments depend on frequent blood transfusions, but her blood type is extremely rare. (Source: NYT Health)
Source: NYT Health - January 6, 2019 Category: Consumer Health News Authors: CHRISTINA CARON Tags: Blood Blood Donation Zainab Mughal Indian B antigen Transfusions Neuroblastoma Miami (Fla) Source Type: news

Fourth donor found for two-year-old cancer sufferer with some of 'the rarest blood in the world'
Zainab Mughal's family, who come from Pakistan, have been told she requires transfusions from seven-to-10 donors if she is to have any hope of beating her neuroblastoma. (Source: the Mail online | Health)
Source: the Mail online | Health - January 4, 2019 Category: Consumer Health News Source Type: news

New insights into childhood cancer
(Charit é - Universit ä tsmedizin Berlin) Peripheral nervous system tumors, known as neuroblastoma, are one of the most common types of childhood tumors. As part of an international research endeavor, researchers from Charit é - Universit ä tsmedizin Berlin have studied the genetic factors behind different tumor subtypes and their prognoses. Their findings enable clinicians to predict the precise clinical course of the disease, and to adapt their treatment regimens accordingly. The study has been published in the prestigious journal Science*. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2018 Category: Cancer & Oncology Source Type: news

Search for extremely rare blood donor for 2-year-old with cancer
An international search is underway for donors with an extremely rare blood type to help save a 2-year-old Florida girl battling aggressive cancer. Zainab Mughal was diagnosed with neuroblastoma two months ago. She has one of the rarest blood types in the world. Nikki Battiste reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - December 7, 2018 Category: Consumer Health News Source Type: news

A mechanistic approach to neuroblastoma prognosis and risk
(American Association for the Advancement of Science) A new study reveals key molecular indicators that could help doctors select the best form of treatment for patients with neuroblastoma -- the most common type of cancer in infants. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

A mechanistic classification of clinical phenotypes in neuroblastoma
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. Its clinical course ranges from spontaneous tumor regression to fatal progression. To investigate the molecular features of the divergent tumor subtypes, we performed genome sequencing on 416 pretreatment neuroblastomas and assessed telomere maintenance mechanisms in 208 of these tumors. We found that patients whose tumors lacked telomere maintenance mechanisms had an excellent prognosis, whereas the prognosis of patients whose tumors harbored telomere maintenance mechanisms was substantially worse. Survival rates were lowest for neuroblastoma patients w...
Source: ScienceNOW - December 6, 2018 Category: Science Authors: Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., Volland, R., Menon, R., Heuckmann, J. M., Gartlgruber, M., Hartlieb, S., Henrich, K.-O., Okonechnikov, K., Altmü Tags: Medicine, Diseases reports Source Type: news

PHOTOS: How this $1M donation at Levine Children's Hospital aids treatment of rare cancer
Levine Children's Hospital now has a specialized treatment suite for an aggressive form of childhood cancer, thanks to a $1 million donation from the Isabella Santos Foundation. The suite is equipped for MIBG treatment, which uses radiation to target high-risk neuroblastoma, a tumor typically found in the adrenal glands. The suite is divided into a lead-lined room for the child and a separate room for the parents to prevent unneeded radiation exposure. An audio-video syst em allows communication… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2018 Category: Biotechnology Authors: Caroline Hudson Source Type: news

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
In this study, we established both phosphoproteomic and gene expression profiles of ALK activity in neuroblastoma cells exposed to first- and third-generation ALK TKIs, to identify the underlying molecular mechanisms and identify relevant biomarkers, signaling networks, and new therapeutic targets. This analysis has unveiled various important leads for novel combinatorial treatment strategies for patients with neuroblastoma and an increased understanding of ALK signaling involved in this disease. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Van den Eynden, J., Umapathy, G., Ashouri, A., Cervantes-Madrid, D., Szydzik, J., Ruuth, K., Koster, J., Larsson, E., Guan, J., Palmer, R. H., Hallberg, B. Tags: STKE Research Resources Source Type: news

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma
Oncogenic anaplastic lymphoma kinase (ALK) is one of the few druggable targets in neuroblastoma, and therapy resistance to ALK-targeting tyrosine kinase inhibitors (TKIs) comprises an inevitable clinical challenge. Therefore, a better understanding of the oncogenic signaling network rewiring driven by ALK is necessary to improve and guide future therapies. Here, we performed quantitative mass spectrometry–based proteomics on neuroblastoma cells treated with one of three clinically relevant ALK TKIs (crizotinib, LDK378, or lorlatinib) or an experimentally used ALK TKI (TAE684) to unravel aberrant ALK signaling pathway...
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Emdal, K. B., Pedersen, A.-K., Bekker-Jensen, D. B., Lundby, A., Claeys, S., De Preter, K., Speleman, F., Francavilla, C., Olsen, J. V. Tags: STKE Research Resources Source Type: news

Hope for non-toxic treatment for child cancer
Drug combination promising in treating neuroblastoma Related items fromOnMedica One in 10 children in phase I cancer trials respond to drugs Child cancer drug approved for NHS use Children need access to cancer drug ‘goldmine’ Higher heart risk for survivors of childhood cancer Make greater effort to protect children from methadone (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 16, 2018 Category: UK Health Source Type: news

Clinical trial harnesses power of natural killer cells to treat neuroblastoma
(Solving Kids' Cancer) Researchers use a humanized monoclonal antibody known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them. The humanized monoclonal antibody may be more effective at activating the NK cells for killing the cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2018 Category: International Medicine & Public Health Source Type: news

Drug combination makes cancer disappear in mice with neuroblastoma
(ECCO-the European CanCer Organisation) Researchers investigating new treatments for neuroblastoma -- one of the most common childhood cancers -- have found that a combination of two drugs made tumors disappear in mice, making it more effective than any other drugs tested in these animals. The research is presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2018 Category: Cancer & Oncology Source Type: news

A nine-year-old boy who bravely endured years of gruelling treatment is now free of cancer
Henry Hallam, from Plymouth, was diagnosed with neuroblastoma when he was three years old. It affects 100 UK children each year and has one of the lowest survival rates - but he beat it. (Source: the Mail online | Health)
Source: the Mail online | Health - October 31, 2018 Category: Consumer Health News Source Type: news

Translational research on recurrent metastatic neuroblastoma at Children's Hospital Los Angeles
(Children's Hospital Los Angeles) A team of investigators at CHLA designed basic research studies to look at the effects of dinutuximab and activated natural killer cells on recurrent disease and overall survival in neuroblastoma. This research provided proof-of-concept for an upcoming clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2018 Category: Cancer & Oncology Source Type: news

Could Zika Virus Potentially Treat Neuroblastoma?
Researchers report that the same driving force that makes Zika so detrimental to unborn babies gives it promise as a cancer treatment. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Girl battling a rare cancer for third time meets Little Mix
Rosie Veronica Mitchell,  Port Glasgow, Inverclyde, is battling neuroblastoma - a rare childhood cancer that usually starts in the abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - August 8, 2018 Category: Consumer Health News Source Type: news

Urgent appeal is underway to send a six-year-old girl abroad for cancer treatment  
Rosie Veronica Mitchell,  Port Glasgow, Inverclyde, is battling neuroblastoma - a rare childhood cancer that usually starts in the abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - August 8, 2018 Category: Consumer Health News Source Type: news

Solid tumors targeted in new CAR T-Cell immunotherapy trial
(Seattle Children's) Seattle Children's has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 7, 2018 Category: International Medicine & Public Health Source Type: news

Beat Childhood Cancer Consortium expands into Canada
(Spectrum Health) Helen DeVos Children's Hospital's consortium, known as Beat Childhood Cancer (BCC), announced today that through a partnership with The C17 Council, the organization's first Canadian clinical trial site, Centre Hospitalier Universitaire de Sainte-Justine, Montreal, Quebec, Canada, has been approved to begin recruiting patients for a pivotal clinical trial investigating the potential of a repurposed drug to prevent relapse in patients diagnosed with high-risk neuroblastoma who are currently in remission. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 6, 2018 Category: International Medicine & Public Health Source Type: news

Zika viruses show potential as treatment for high-risk childhood cancer
(Nemours) Zika virus may hold potential as a cancer treatment for neuroblastoma, a rare-but-deadly childhood cancer, according to early findings from basic research published today in PLOS ONE. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 25, 2018 Category: Cancer & Oncology Source Type: news

Cancer drug for children recommended after becoming cost effective for NHS patients
Seriously ill children battling high-risk neuroblastoma, a rare type of cancer that mainly affects children and young people, are to be offered a drug which has potential to extend their lives. (Source: NHS Networks)
Source: NHS Networks - July 12, 2018 Category: UK Health Source Type: news

Child cancer drug approved for NHS use
60% of children with high-risk neuroblastoma can be treated with dinutuximab beta Related items fromOnMedica One in 10 children in phase I cancer trials respond to drugs Children need access to cancer drug ‘goldmine’ NICE rejects adjuvant use of breast cancer drug New breast cancer drug ‘unaffordable’ for NHS Drug could double head and neck cancer survival (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 12, 2018 Category: UK Health Source Type: news

Fluorescent fish genes light path to neuroblastoma
(Rice University) Neurodevelopmental biologist Rosa Uribe, a CPRIT Scholar who was recruited to Rice University in 2017 with a grant from the Cancer Prevention and Research Institute of Texas, has a new tool in the search for the origins of neuroblastoma, the third-most common pediatric cancer in the United States. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

New model for predicting neuroblastoma outcomes incorporates early developmental signals
(Stowers Institute for Medical Research) Motivated by a desire to better understand the molecular circuitry underlying neuroblastoma and limitations of current methods for predicting disease progression and outcome, researchers from the Kulesa Lab at the Stowers Institute for Medical Research and collaborators at the University of Michigan and Oxford University set out to construct a logic-based model incorporating information about developmental signaling pathways implicated in the disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 6, 2018 Category: Biology Source Type: news

MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
SAN DIEGO, July 3, 2018 -- (Healthcare Sales & Marketing Network) -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical stage oncology drug development company has granted to Y-mAbs Therapeutics, Inc., a privately held clinical stage biopharmac... Biopharmaceuticals, Oncology, Licensing MabVax Therapeutics, Y-mAbs Therapeutics, neuroblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2018 Category: Pharmaceuticals Source Type: news

Emerging Role of Immunotherapy for Childhood Cancers Emerging Role of Immunotherapy for Childhood Cancers
Immunotherapeutic strategies are showing promise for pediatric cancers such as leukemia and neuroblastoma. What is the latest research?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Novel nuclear medicine approach shows promise for treating wide array of cancerous tumors
(Society of Nuclear Medicine and Molecular Imaging) A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer--including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children. The research was presented today at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2018 Category: Cancer & Oncology Source Type: news

Researchers create novel combination as potential therapy for high-risk neuroblastoma
(Virginia Commonwealth University) Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2018 Category: International Medicine & Public Health Source Type: news

St Louis Cardinals pitcher reveals his one-year-old daughter is battling  cancer
St Louis Cardinals starting pitcher Alex Reyes, 23, revealed publicly for the first time that his one-year-old daughter Aleyka was diagnosed with neuroblastoma when she was just five months old. (Source: the Mail online | Health)
Source: the Mail online | Health - June 13, 2018 Category: Consumer Health News Source Type: news

Childhood Cancer Impacts Mental Health
WEDNESDAY, June 13, 2018 -- Children with neuroblastoma, a pediatric cancer of nerve cells, are vulnerable to mental health and behavioral problems, a new study finds. Neuroblastoma is diagnosed at a median age of 17.3 months. Treatment advances... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 13, 2018 Category: General Medicine Source Type: news

Childhood Neuroblastoma Survivors at Higher Risk for Psych Disorders
(MedPage Today) -- Chronic health conditions predicted impairment (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - June 13, 2018 Category: Psychiatry Source Type: news

Child Neuroblastoma Survivors at Risk for Psych Impairment
MONDAY, June 11, 2018 -- Neuroblastoma survivors are at elevated risk for psychological impairment, according to a study published online June 11 in Cancer. Daniel J. Zheng, M.D., from Yale University in New Haven, Conn., and colleagues evaluated... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 11, 2018 Category: Pharmaceuticals Source Type: news

Children with neuroblastoma have an elevated risk of long-term psychological difficulties
(Wiley) A new study reveals that pediatric neuroblastoma patients are at elevated risk for long-term psychological impairment. In addition, those who experience such impairment as they get older tend to require special education services and to not go on to college. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2018 Category: Cancer & Oncology Source Type: news

Transatlantic clinical trial for neuroblastoma is open in UK -- US and Germany to open soon
This study combines 131-I mIBG with Nivolumab and Dinutuximab beta. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2018 Category: Cancer & Oncology Source Type: news

Decision to not make drug for childhood cancer on NHS 'devastating'
Health watchdog Nice, which advises NHS England, stressed it would like to recommend dinutuximab beta for patients with neuroblastoma – but argued it is too expensive. (Source: the Mail online | Health)
Source: the Mail online | Health - May 4, 2018 Category: Consumer Health News Source Type: news

Decision to not make a drug for childhood cancer on the NHS is 'devastating', say charities
Health watchdog Nice, which advises NHS England, stressed it would like to recommend dinutuximab beta for patients with neuroblastoma – but argued it is too expensive. (Source: the Mail online | Health)
Source: the Mail online | Health - May 4, 2018 Category: Consumer Health News Source Type: news